| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
L-Homoarginine targets multiple enzymes and pathways. It acts as a competitive substrate for nitric oxide synthase (NOS), competing with arginine for the active site. It is also a potent inhibitor of human bone and liver alkaline phosphatase. Additionally, homoarginine plays a role in the synthesis of nitric oxide, which is crucial for vascular function and signaling. Its effects on these targets contribute to its role in cardiovascular health.
|
|---|---|
| ln Vitro |
In human bones and liver, H-HoArg-OH (L-homoarginine) is a potent inhibitor of alkaline phosphatase and a homologue of arginine; however, unlike H-HoArg-OH, it does not Tract and placental alkaline phosphatase had less effect. inhibits bone and liver enzymes but not intestine or placental alkaline phosphatase. The primary sources of serum alkaline phosphatase are the aforementioned four tissues [1]. Low amounts of the endogenous amino acid H-HoArg-OH have also been linked to cardiovascular disease [2].
L-Homoarginine is a potent inhibitor of human bone and liver alkaline phosphatase. It acts as a competitive substrate for nitric oxide synthase (NOS). Its activity as a NOS substrate has been confirmed in various biochemical assays. It also plays a role in polyamine metabolism. Elevated levels of L-homoarginine have been associated with improved endothelial function and reduced cardiovascular risk. |
| ln Vivo |
L-Homoarginine has been studied for its potential role in cardiovascular health, as it has been associated with improved endothelial function and reduced risk of cardiovascular diseases. It has been investigated for its effects on nitric oxide synthesis and vascular health. Elevated levels of L-homoarginine have been linked to reduced cardiovascular risk, making it a valuable biomarker for assessing cardiovascular health.
|
| Enzyme Assay |
The primary in vitro assays for L-Homoarginine include NOS activity assays, where the compound's ability to serve as a substrate for NOS is measured by monitoring the production of citrulline or nitric oxide. Alkaline phosphatase inhibition assays are performed by incubating the enzyme with a chromogenic substrate and measuring the inhibition of product formation in the presence of the compound.
|
| Cell Assay |
In vitro cellular experiments for L-Homoarginine involve treating endothelial cells or other relevant cell types with the compound and measuring its effects on nitric oxide production, endothelial function, and cell signaling. The compound's effects on alkaline phosphatase activity can be assessed in bone or liver cell cultures. Its role in polyamine metabolism can be studied in various cell lines.
|
| Animal Protocol |
In vivo animal experiments for L-Homoarginine would involve administering the compound to animal models to assess its effects on cardiovascular function, nitric oxide production, and endothelial health. Its effects on blood pressure regulation and vascular function would be evaluated. However, specific in vivo data is limited in the available literature.
|
| ADME/Pharmacokinetics |
L-Homoarginine has a molecular weight of 174.20 g/mol and a molecular formula of C7H16N4O2. It is a solid at room temperature with a predicted melting point of 296.73°C. It is typically stored at 4°C. The compound is soluble in water and is commonly used as a research reagent in biochemical and pharmacological studies.
|
| Toxicity/Toxicokinetics |
L-Homoarginine is a research compound that is not intended for human therapeutic use. As a naturally occurring amino acid, it is generally considered to have low toxicity. However, as with all research chemicals, standard safety precautions should be followed when handling. Its safety profile for therapeutic applications would need to be established through preclinical studies.
|
| References | |
| Additional Infomation |
L-Homoarginine is a derivative of L-lysine and the L-enantiomer of homoarginine. It is an EC 3.1.3.1 (alkaline phosphatase) inhibitor and is also a human metabolite, an exogenous metabolite, a rat metabolite, and a biomarker. It is an L-lysine derivative, a non-protein L-α-amino acid, and also a homoarginine. It is the conjugate base of L-homogeneous (1+). L-Homoarginine has been reported to exist in Lathyrus sativus, Lathyrus tingitanus, and other organisms with relevant data.
L-Homoarginine is a non-essential, non-proteinogenic amino acid that acts as a competitive substrate for nitric oxide synthase and a potent inhibitor of alkaline phosphatase. It has been studied for its potential role in cardiovascular health, as elevated levels have been linked to reduced cardiovascular risk. The compound is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C7H16N4O2
|
|---|---|
| Molecular Weight |
188.23
|
| Exact Mass |
188.127
|
| CAS # |
156-86-5
|
| Related CAS # |
H-HomoArg-OH.HCl;1483-01-8;H-HoArg-OH-d4;1332075-41-8
|
| PubChem CID |
9085
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
376.3±52.0 °C at 760 mmHg
|
| Melting Point |
213 - 215 °C
|
| Flash Point |
181.4±30.7 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
-1.86
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
13
|
| Complexity |
189
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CCN=C(N)N)C[C@@H](C(=O)O)N
|
| InChi Key |
QUOGESRFPZDMMT-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C7H16N4O2/c8-5(6(12)13)3-1-2-4-11-7(9)10/h5H,1-4,8H2,(H,12,13)(H4,9,10,11)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-amino-6-(diaminomethylideneamino)hexanoic acid
|
| Synonyms |
NSC-27429; L-Homoarginine; Homoarginine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~531.26 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (531.26 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3126 mL | 26.5632 mL | 53.1265 mL | |
| 5 mM | 1.0625 mL | 5.3126 mL | 10.6253 mL | |
| 10 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
